Phaseline

Targets › 5T4

5T4: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on 5T4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Chiome BioscienceCBA-1535
T cell engager (bispecific antibody engaging 5T4 and CD3)
TRAC, 5T4Phase 1Solid TumorsDec 2026

Conditions

Solid Tumors (1)

Modalities

mixed (1)

Companies

Chiome Bioscience (1)

Related targets

TRAC (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.